FDA-cleared profile

SpineUs™ System

Verdure Imaging · Ultrasound · FDA-cleared (510(k))

Authorized purpose: Tracked B-mode ultrasound acquisition, display, and scoliosis-angle measurement of the spine for trained users as an adjunct to conventional imaging; it is not the sole basis for patient management.

Clinical role
Adjunctive tracked-ultrasound acquisition, three-dimensional reconstruction, and scoliosis-angle measurement.
Images and patients
Ultrasound · Spine
Key limitation
Keep in mind: Use is adjunctive to conventional imaging and not the sole basis for patient management. The FDA study included 31 test subjects and showed larger mean absolute measurement differences in the greater-than-40-degree curvature subgroup.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Tracked B-mode ultrasound acquisition, display, and scoliosis-angle measurement of the spine for trained users as an adjunct to conventional imaging; it is not the sole basis for patient management.
  • Which images or clinical context are in scope?Modality: Ultrasound Anatomy or clinical context: Spine Input: B-mode spinal ultrasound acquired with the tracked SpineUs transducer and compatible ultrasound components.
  • Who uses it?Intended users: Trained chiropractors and radiologists qualified to perform and interpret musculoskeletal ultrasound.
  • What does the software produce?Output: Three-dimensional reconstructed spinal images, AI-segmented bone surfaces, and user-reviewed scoliosis-angle measurements.
  • What is its most important limitation?Key limitation: Use is adjunctive to conventional imaging and not the sole basis for patient management. The FDA study included 31 test subjects and showed larger mean absolute measurement differences in the greater-than-40-degree curvature subgroup.

Clinical takeaway. Clinical role: Tracked B-mode ultrasound acquisition, display, and scoliosis-angle measurement of the spine for trained users as an adjunct to conventional imaging; it is not the sole basis for patient management.

Evidence takeaway. Evidence from the reviewed source record: FDA-described testing used a 31-subject test set independent from development data. Transverse processes were identified in all test cases; pixel-level bone segmentation sensitivity was 41.80% and specificity was 99.19%. Three observers compared ultrasound and radiograph scoliosis-angle measurements, with mean absolute differences increasing in the greater-than-40-degree curvature subgroup.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Tracked B-mode ultrasound acquisition, display, and scoliosis-angle measurement of the spine for trained users as an adjunct to conventional imaging; it is not the sole basis for patient management.
  • Exact FDA submission
  • Checked 2026-09-08
Workflow role
Adjunctive tracked-ultrasound acquisition, three-dimensional reconstruction, and scoliosis-angle measurement.
  • Exact FDA submission
  • Checked 2026-09-08
Required input
B-mode spinal ultrasound acquired with the tracked SpineUs transducer and compatible ultrasound components.
  • Exact FDA submission
  • Checked 2026-09-08
Output and clinician action
Three-dimensional reconstructed spinal images, AI-segmented bone surfaces, and user-reviewed scoliosis-angle measurements.
  • Exact FDA submission
  • Checked 2026-09-08
Care setting
Hospitals and clinics performing superficial musculoskeletal ultrasound of the spine.
  • Exact FDA submission
  • Checked 2026-09-08
Intended users
Trained chiropractors and radiologists qualified to perform and interpret musculoskeletal ultrasound.
  • Exact FDA submission
  • Checked 2026-09-08
Limitations
Use is adjunctive to conventional imaging and not the sole basis for patient management. The FDA study included 31 test subjects and showed larger mean absolute measurement differences in the greater-than-40-degree curvature subgroup.
  • Exact FDA submission
  • Checked 2026-09-08
Evidence summary
FDA-described testing used a 31-subject test set independent from development data. Transverse processes were identified in all test cases; pixel-level bone segmentation sensitivity was 41.80% and specificity was 99.19%. Three observers compared ultrasound and radiograph scoliosis-angle measurements, with mean absolute differences increasing in the greater-than-40-degree curvature subgroup.
  • Exact FDA submission
  • Checked 2026-09-08

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
FDA-described testing used a 31-subject test set independent from development data. Transverse processes were identified in all test cases; pixel-level bone segmentation sensitivity was 41.80% and specificity was 99.19%. Three observers compared ultrasound and radiograph scoliosis-angle measurements, with mean absolute differences increasing in the greater-than-40-degree curvature subgroup.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Reported sensitivity
41.80% pixel-level bone-segmentation sensitivity; this is not patient-level diagnostic sensitivity.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Reported specificity
99.19% pixel-level bone-segmentation specificity; this is not patient-level diagnostic specificity.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08

Transverse processes identified

100 percent

  • EndpointPercentage of transverse processes correctly identified in reconstructed three-dimensional ultrasound
  • PopulationIndependent nonclinical and clinical test dataset
  • Tested versionSpineUs configuration submitted in K241029

Pixel-level segmentation sensitivity

41.8 percent

  • EndpointBone-surface pixel segmentation sensitivity
  • PopulationIndependent ultrasound test dataset with expert pixel annotations
  • Tested versionSpineUs configuration submitted in K241029

Pixel-level segmentation specificity

99.19 percent

  • EndpointBone-surface pixel segmentation specificity
  • PopulationIndependent ultrasound test dataset with expert pixel annotations
  • Tested versionSpineUs configuration submitted in K241029

Mean absolute scoliosis-angle difference for curvature over 40 degrees

5.57 degrees

  • EndpointAbsolute difference between SpineUs and radiograph scoliosis-angle measurements
  • PopulationSubjects with radiographic spinal curvature greater than 40 degrees
  • Tested versionSpineUs configuration submitted in K241029

SpineUs segmentation and scoliosis-angle validation

  • DesignIndependent test-set evaluation of AI bone-surface segmentation and three-observer comparison of ultrasound and radiograph scoliosis-angle measurements.
  • Population31 subjects spanning less-than-20-degree, 20-to-40-degree, and greater-than-40-degree spinal-curvature subgroups.
  • Scopeexact submission
  • Tested versionSpineUs configuration submitted in K241029
  • Samplen=31
  • IndependenceSponsor or vendor study

K241029

FDA submission evidence; not an independent clinical-outcomes study.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K241029. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-08
Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: B-mode spinal ultrasound acquired with the tracked SpineUs transducer and compatible ultrasound components.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-08 · FDA K241029: SpineUs™ System

  2. Routing

    Source context, not route validation: The cleared system combines a tracked ultrasound transducer, workstation software, and B-mode input; the reviewed FDA summary does not establish PACS, RIS, or EHR interfaces.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-08 · FDA K241029: SpineUs™ System

  3. AI processing

    Unresolved route: Not established for the exact route.

    Scope: Exact FDA submission. The reviewed sources do not establish the current exact-release hosting topology, data flow, region, tenancy, or disaster-recovery configuration.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-08 ·

  4. Returned objects

    Source context, not route validation: Three-dimensional reconstructed spinal images, AI-segmented bone surfaces, and user-reviewed scoliosis-angle measurements.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-08 · FDA K241029: SpineUs™ System

  5. Viewer/worklist/report

    Unresolved route: Three-dimensional reconstructed spinal images, AI-segmented bone surfaces, and user-reviewed scoliosis-angle measurements.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-08 · FDA K241029: SpineUs™ System

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Integration
The cleared system combines a tracked ultrasound transducer, workstation software, and B-mode input; the reviewed FDA summary does not establish PACS, RIS, or EHR interfaces.
  • Exact FDA submission
  • Checked 2026-09-08

Current product-family workflow context

Verdure describes the current SpineUs family as AI-enabled three-dimensional spinal ultrasound with AI segmentation and real-time reconstruction.

product family · checked 2026-09-08

Confirm exact-release availability, interfaces, hosting, security, support, and commercial terms during procurement.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K241029
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
Ultrasound
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Anatomy
Spine
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2024-10-07
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-20Last searched
20Fields reviewed
9Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, vendor product page, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-08 - Exact FDA submission

    No public price or quote for the exact K241029 configuration was established in this review.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-09-08 - Exact FDA submission

    No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.

  • Deployment: Not verified - checked 2026-09-08 - Exact FDA submission

    The reviewed sources do not establish the current exact-release hosting topology, data flow, region, tenancy, or disaster-recovery configuration.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not verified - checked 2026-09-08 - Exact FDA submission

    Exact-release security controls, data retention, hosting boundaries, and scoped assurance documentation require vendor confirmation.

  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-09-08 - Exact FDA submission

    Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.

  • Monitoring: Not verified - checked 2026-09-08 - Exact FDA submission

    Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.

7 sources - 3 history items

Source ledger

  1. FDA K241029: SpineUs™ System

    U.S. Food and Drug Administration - Published 2024-10-07 - Accessed 2026-09-08

    Scope: identity, clinicalUse, modality, anatomy, workflow, evidence, implementation

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  4. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  5. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  6. openFDA exact recall query for K241029

    U.S. Food and Drug Administration - Accessed 2026-09-08

    Scope: postmarketSafety

  7. SpineUs AI-enabled 3D ultrasound

    Verdure Imaging - Accessed 2026-09-08

    Scope: productFamily, clinicalWorkflow, implementationCapabilities

Research history

  1. K241029 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K243937

Accuro 3S

Rivanna Medical, Inc.

Authorized purpose: Accuro 3S is portable B-mode ultrasound with SpineNav-AI for lumbar-spine scouting and epidural-depth estimation during neuraxial-anesthesia and needle or catheter placement workflows.

Modality
Ultrasound
Anatomy
Spine
Decision
2025-05-23
FDA-cleared K252237

EdgeFlow UW20

Edgecare, Inc.

Authorized purpose: EdgeFlow UW20 is a wearable ultrasound system for noninvasive periodic bladder-volume measurement in adults with BMI no greater than 30.

Modality
Ultrasound
Anatomy
Urinary bladder
Decision
2026-04-17
FDA-cleared K253535

Ligence Heart

Ligence Uab

Ligence Heart is a fully automated software platform that processes, analyses and makes measurements on acquired transthoracic cardiac ultrasound images, automatically producing a full report with measurements of several key cardiac structural and functional parameters. The data produced by this software is intended to be used to support qualified cardiologists or sonographers for clinical decision making. Ligence Heart is indicated for use in adult patients. Ligence Heart has not been validated for the assessment of congenital heart disease, valve disease, pericardial disease, and/or intra-cardiac lesions (e.g., tumors, thrombi). Limitations: Poor image capture will lead to poor annotations and subsequent measurements. Multiple image quality algorithms are used to filter out images of poor quality. Our software complements good patient care and does not exempt the user from the responsibility to provide supervision, clinically review the patient, and make appropriate clinical decisions. If no gender is present, female referenced guideline values will be used for conclusions. If Body Surface Area (BSA) is not present, indexed values cannot be provided. During image acquisition, inappropriate use of the echo machine, use of non-cardiac ultrasound probes, or use of suboptimal settings (e.g., gain, contrast, depth) may lead to lower accuracy of the software. Ligence Heart has not been validated in patients with prosthetic or surgically altered cardiac valves, implantable intracardiac devices, or irregular (non-sinus) rhythm; these conditions may affect automated measurement accuracy.

Modality
Ultrasound
Anatomy
Heart/Cardiovascular
Decision
2026-02-27

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history